Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma

The objective of this study was to investigate the prevalence of pathogenic germline variants (PGVs) in 32 cancer susceptibility genes in individuals with newly diagnosed pancreatic ductal adenocarcinoma (PDAC). A key secondary objective was to evaluate how often PGVs would have been undetected with existing genetic testing criteria.

• Publication year

  2018

• Venue

  Cancer

• Publication date

  2018-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.31628PMID 30067863
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reflex Testing for Germline BRCA1, BRCA2, PALB2, and ATM Mutations in Pancreatic Cancer: Mutation Prevalence and Clinical Outcomes From Two Canadian Research Registries.

  2018cited by this paper
• Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations.

  2018cited by this paper
• Should We Lower Our Threshold for Germline Genetic Assessment in Pancreatic Adenocarcinoma?

  2018cited by this paper
• Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms

  2018cited by this paper
• Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.

  2017cited by this paper
• Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma.

  2017cited by this paper
• Germline Testing for Individuals With Pancreatic Cancer: The Benefits and Challenges to Casting a Wider Net.

  2017cited by this paper
• Identification, genetic testing, and management of hereditary melanoma

  2017cited by this paper
• Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing

  2017influential reference
• The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes

  2017cited by this paper
• Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.

  2016cited by this paper
• Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer.

  2016cited by this paper
• Beyond DNA: An Integrated and Functional Approach for Classifying Germline Variants in Breast Cancer Genes

  2016cited by this paper
• Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients

  2015cited by this paper
• Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.

  2015cited by this paper
• Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.

  2015cited by this paper
• KBG Syndrome: A Case Report and Longitudinal Assessment of Long‐Acting Recombinant Human Growth Hormone Therapy

  2015cited by this paper
• ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes

  2015cited by this paper
• BRCA1, BRCA2, PALB2, and CDKN2A Mutations in Familial Pancreatic Cancer (FPC): A PACGENE Study

  2014cited by this paper
• Pancreatic cancer risk in hereditary pancreatitis

  2014cited by this paper
• International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer

  2012influential reference
• Genetic susceptibility to pancreatic cancer

  2012cited by this paper
• Peutz–Jeghers syndrome: a systematic review and recommendations for management

  2010cited by this paper
• Selection criteria for genetic assessment of patients with familial melanoma.

  2009cited by this paper
• Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis

  2008cited by this paper
• Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results

  2008cited by this paper
• Genetic/familial high-risk assessment: breast and ovarian.

  2006cited by this paper
• Sensitivity and predictive value of criteria for p53germline mutation screening

  2001cited by this paper

• GERMLINE PATHOGENIC VARIANTS IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA AND EXTRA-PANCREATIC MALIGNANCIES: A NATIONWIDE DATABASE ANALYSIS.

  2025cites this paper
• 17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome—a case for universal genetic testing?

  2025cites this paper
• From genetic risk to clinical action: universal germline testing and surveillance in pancreatic cancer

  2025cites this paper
• Diagnosis and treatment strategies for hereditary pancreatic cancer syndrome.

  2025cites this paper
• DNA Damage and Repair in Pancreatic Cancer—The Latest Findings

  2025cites this paper
• Universal Genetic Testing for Pancreatic Cancer: Closing the Gap on a Missed Opportunity.

  2025cites this paper
• Prevalence of Pathogenic Germline Variants in Patients With Gastric Cancer Ascertained Through Multigene Panel Testing

  2025cites this paper
• A Mixed-Methods Approach to Assessing Barriers and Facilitators to Cancer Genetics Care in Black and Latino/a Individuals Impacted by Pancreatic Cancer: The Racial/ethnic Equity in GENetic Education, Risk Assessment, and TEsting (REGENERATE) Study

  2025cites this paper
• Genetic medicine of familial and hereditary pancreatic cancer: Recent update in the era of precision cancer medicine

  2025cites this paper
• Understanding familial risk of pancreatic ductal adenocarcinoma

  2024influential citation
• Prevalence of germline variants in Brazilian pancreatic carcinoma patients

  2024influential citation
• PANCREATIC CANCER SCREENING: A NARRATIVE REVIEW

  2024cites this paper
• Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy

  2024cites this paper
• Expanding access to genetic testing for pancreatic cancer

  2024cites this paper
• Bridging the Divide: From Universal Germline Testing Guidance to Real-World Implementation in Pancreatic Cancer Care.

  2024cites this paper
• Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma

  2024cites this paper
• Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan

  2024cites this paper
• A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing

  2023influential citation
• Surveillance Outcome and Genetic Findings in Individuals at High Risk of Pancreatic Cancer

  2023cites this paper
• Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review

  2023cites this paper
• Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations

  2023cites this paper
• Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.

  2023cites this paper
• Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer

  2023cites this paper
• Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next‐generation sequencing

  2023influential citation
• Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients with Pancreatic Cancer or Suspected Related Hereditary Syndromes: Historical Prospective Analysis

  2023cites this paper
• Outcomes of Universal Point-of-Care Genetic Testing in Diverse Patients With Pancreatic Ductal Adenocarcinoma

  2023cites this paper
• Current Screening Strategies for Pancreatic Cancer

  2022cites this paper
• Lynch Syndrome-Associated Cancers Beyond Colorectal Cancer.

  2022cites this paper
• Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance

  2022cites this paper
• Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors

  2022cites this paper
• Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model.

  2022cites this paper
• Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for all GI Cancers?

  2022cites this paper
• Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors

  2022cites this paper
• Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care

  2022cites this paper
• Building on More Than 20 Years of Progress in Pancreatic Cancer Surveillance for High-Risk Individuals.

  2022cites this paper
• Impact of comprehensive family history and genetic analysis in the multidisciplinary pancreatic tumor clinic setting

  2022cites this paper
• The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice.

  2022cites this paper
• Contribution of germline PALB2 variants to an unselected and prospectively registered pancreatic cancer patient cohort in Pakistan.

  2022cites this paper
• Pancreatic Adenocarcinoma: Trends in Epidemiology, Risk Factors, and Outcomes.

  2022cites this paper
• Germline Testing for Individuals with Pancreatic Adenocarcinoma and Novel Genetic Risk Factors.

  2022cites this paper
• Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals.

  2022cites this paper
• Integrated genomic analysis to identify druggable targets for pancreatic cancer

  2022cites this paper
• Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes

  2021cites this paper
• Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer

  2021cites this paper
• BRCA mutated pancreatic cancer: A change is coming

  2021cites this paper
• Genetic Variants in Patients With a Family History of Pancreatic Cancer

  2021cites this paper
• Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities.

  2021cites this paper
• Cancer surveillance awareness and practice among families at increased risk for pancreatic adenocarcinoma

  2021cites this paper
• Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer.

  2021cites this paper
• Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma

  2021cites this paper
• Germline Mutations Including the Rare Pathogenic Variant c.3206delC in the ATM Gene Cause Ataxia Teleangiectasia-Associated Primary Central Nervous System Lymphoma

  2021cites this paper
• Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis

  2021cites this paper
• A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer

  2021cites this paper
• BRCA-mutant pancreatic ductal adenocarcinoma

  2021cites this paper
• Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants

  2021cites this paper
• Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients

  2021cites this paper
• Inherited Pancreatic Cancer Syndromes and High-Risk Screening.

  2021cites this paper
• Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing

  2021cites this paper
• Elevated METTL16 expression in PDAC confers synthetic lethality to PARP inhibition by antagonizing MRE11-mediated DNA end resection

  2021cites this paper
• Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer from the PRECEDE (Pancreatic Cancer Early Detection) Consortium.

  2021cites this paper
• The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer

  2021cites this paper
• Universal Germline Testing of Unselected Cancer Patients Detects Pathogenic Variants Missed by Standard Guidelines without Increasing Healthcare Costs

  2021cites this paper
• Germline Variants in DNA Damage Repair Genes: An Emerging Role in the Era of Precision Medicine in Pancreatic Adenocarcinoma

  2021influential citation
• Genetic evaluation of patients and families with concern for hereditary endocrine tumor syndromes

  2021cites this paper
• Staging Classification and Stratification of Pancreatic Cancer for Clinical Practice

  2021cites this paper
• The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.

  2020cites this paper
• An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review.

  2020cites this paper
• ATM Serine/Threonine Kinase and its Role in Pancreatic Risk

  2020cites this paper
• Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.

  2020cites this paper
• Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes

  2020influential citation
• Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer

  2020cites this paper
• Germline genetic variability in pancreatic cancer risk and prognosis.

  2020cites this paper
• DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives

  2020cites this paper
• Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies

  2019cites this paper
• Multigene panel testing versus syndrome-specific germline testing for inherited cancer risk: 'a somewhat different way'.

  2019cites this paper
• Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer

  2019cites this paper
• Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma

  2019cites this paper
• Pancreatic Cancer Surveillance: Who, When, and How

  2019cites this paper
• Current Approaches to Germline Cancer Genetic Testing.

  2019cites this paper
• Management of pancreatic ductal adenocarcinoma (PDAC): Progress in the past decade and challenges for the future

  2019cites this paper
• Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants

  2019cites this paper
• The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.

  2019cites this paper
• Genetics of Familial and Sporadic Pancreatic Cancer.

  2019cites this paper
• Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance.

  2019cites this paper
• Functional CDKN 2 A assay identifies frequent deleterious alleles misclassified as variants 1 of uncertain significance 2 3

  year unknowncites this paper